Skip to main
  1. Stocks
  2. Upstream Bio Inc
  3. Forecast
UPB

UPB Stock Forecast & Price Target

UPB Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Upstream Bio is attractive because verekitug has already delivered clinically meaningful Phase 2 efficacy in severe asthma and CRSwNP, including a 56% reduction in annualized asthma exacerbations at 100mg every 12 weeks and strong nasal polyp and congestion improvements, while preserving a favorable safety and tolerability profile. Management has also achieved key clinical, regulatory, and manufacturing milestones ahead of planned Phase 3 initiation in 1Q27, and the company’s $207.4 million of cash and equivalents is expected to fund operations through 2027, reducing near-term financing pressure. The investment case is further strengthened by verekitug’s differentiated quarterly dosing versus monthly or more frequent competitor biologics and by additional upside from the fully enrolled 481-patient COPD trial, with data expected in 2H27.

Bears say

Upstream Bio is viewed negatively because its limited cash runway and the capital intensity of advancing pivotal asthma and CRSwNP programs create a financing overhang, with management expecting cash to fund operations through 2027 but not enough to complete both Phase 3 trials without a substantial equity raise in 2H27. The company also faces heightened execution and clinical risk after the market’s reaction to the February 11, 2026 Phase 2 VALIANT data, when the stock fell about 70% from February 10, 2026 to February 17, 2026 despite positive topline results, signaling investor concern about durability and dose consistency. Fundamentally, verekitug must still prove it can compete in severe asthma, CRSwNP, and COPD while overcoming regulatory, competitive, IP, and pricing pressures, and the need to raise capital at a higher discount rate increases dilution risk and reduces shareholder value.

UPB has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Upstream Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

UPB Analyst Forecast & Price Prediction

Get the latest UPB stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in UPB

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Upstream Bio Inc (UPB) Forecast

Analysts have given UPB a Buy based on their latest research and market trends.

According to 6 analysts, UPB has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Upstream Bio Inc (UPB)


UPB Analyst Forecast & Price Prediction

Get the latest UPB stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in UPB

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover UPB stock data and trends